vs
Side-by-side financial comparison of FIRST BANCORP (FBNC) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
FIRST BANCORP is the larger business by last-quarter revenue ($89.6M vs $75.5M, roughly 1.2× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -7.3%). FIRST BANCORP produced more free cash flow last quarter ($48.2M vs $14.4M).
First Bancorp is an American bank holding company headquartered in Southern Pines, North Carolina, that operates as First Bank in North Carolina and South Carolina.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
FBNC vs PBYI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $89.6M | $75.5M |
| Net Profit | $20.4M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 29.0% | 22.7% |
| Net Margin | 22.7% | — |
| Revenue YoY | -7.3% | 27.7% |
| Net Profit YoY | 9.0% | — |
| EPS (diluted) | $0.49 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $75.5M | ||
| Q3 25 | $89.6M | $54.5M | ||
| Q2 25 | $111.0M | $52.4M | ||
| Q1 25 | $105.8M | $46.0M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | $96.6M | $80.5M | ||
| Q2 24 | $95.7M | $47.1M | ||
| Q1 24 | $92.2M | $43.8M |
| Q4 25 | — | — | ||
| Q3 25 | $20.4M | $8.8M | ||
| Q2 25 | $38.6M | $5.9M | ||
| Q1 25 | $36.4M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $18.7M | $20.3M | ||
| Q2 24 | $28.7M | $-4.5M | ||
| Q1 24 | $25.3M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | — | 22.7% | ||
| Q3 25 | 29.0% | 17.6% | ||
| Q2 25 | 44.9% | 12.7% | ||
| Q1 25 | 44.2% | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | 23.4% | 27.4% | ||
| Q2 24 | 38.5% | -4.6% | ||
| Q1 24 | 34.5% | -5.3% |
| Q4 25 | — | — | ||
| Q3 25 | 22.7% | 16.2% | ||
| Q2 25 | 34.7% | 11.2% | ||
| Q1 25 | 34.4% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 19.3% | 25.2% | ||
| Q2 24 | 30.0% | -9.6% | ||
| Q1 24 | 27.4% | -11.0% |
| Q4 25 | — | $0.26 | ||
| Q3 25 | $0.49 | $0.17 | ||
| Q2 25 | $0.93 | $0.12 | ||
| Q1 25 | $0.88 | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | $0.45 | $0.41 | ||
| Q2 24 | $0.70 | $-0.09 | ||
| Q1 24 | $0.61 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $97.5M |
| Total DebtLower is stronger | $92.4M | $22.7M |
| Stockholders' EquityBook value | $1.6B | $130.3M |
| Total Assets | $12.8B | $216.3M |
| Debt / EquityLower = less leverage | 0.06× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M | ||
| Q1 24 | — | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | $92.4M | $34.0M | ||
| Q2 25 | $92.2M | $45.3M | ||
| Q1 25 | $92.1M | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | $91.7M | $79.3M | ||
| Q2 24 | $91.5M | $90.7M | ||
| Q1 24 | $332.3M | $102.0M |
| Q4 25 | — | $130.3M | ||
| Q3 25 | $1.6B | $115.3M | ||
| Q2 25 | $1.6B | $104.7M | ||
| Q1 25 | $1.5B | $97.1M | ||
| Q4 24 | — | $92.1M | ||
| Q3 24 | $1.5B | $71.1M | ||
| Q2 24 | $1.4B | $48.5M | ||
| Q1 24 | $1.4B | $51.0M |
| Q4 25 | — | $216.3M | ||
| Q3 25 | $12.8B | $202.9M | ||
| Q2 25 | $12.6B | $194.9M | ||
| Q1 25 | $12.4B | $196.2M | ||
| Q4 24 | — | $213.3M | ||
| Q3 24 | $12.2B | $220.7M | ||
| Q2 24 | $12.1B | $205.0M | ||
| Q1 24 | $12.1B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | 0.06× | 0.30× | ||
| Q2 25 | 0.06× | 0.43× | ||
| Q1 25 | 0.06× | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | 0.06× | 1.12× | ||
| Q2 24 | 0.07× | 1.87× | ||
| Q1 24 | 0.24× | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $49.7M | $14.4M |
| Free Cash FlowOCF − Capex | $48.2M | $14.4M |
| FCF MarginFCF / Revenue | 53.8% | 19.1% |
| Capex IntensityCapex / Revenue | 1.6% | 0.0% |
| Cash ConversionOCF / Net Profit | 2.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | $182.9M | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.4M | ||
| Q3 25 | $49.7M | $9.7M | ||
| Q2 25 | $45.7M | $14.1M | ||
| Q1 25 | $52.6M | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $38.4M | $11.0M | ||
| Q2 24 | $87.7M | $1.0M | ||
| Q1 24 | $-20.1M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | $48.2M | $9.7M | ||
| Q2 25 | $44.3M | $14.1M | ||
| Q1 25 | $52.4M | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | $38.0M | $11.0M | ||
| Q2 24 | $87.6M | $1.0M | ||
| Q1 24 | $-21.7M | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | 53.8% | 17.7% | ||
| Q2 25 | 39.9% | 26.8% | ||
| Q1 25 | 49.5% | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | 39.3% | 13.7% | ||
| Q2 24 | 91.6% | 2.1% | ||
| Q1 24 | -23.6% | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 1.6% | 0.0% | ||
| Q2 25 | 1.2% | 0.0% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.5% | 0.0% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 1.8% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.44× | 1.10× | ||
| Q2 25 | 1.19× | 2.41× | ||
| Q1 25 | 1.44× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.06× | 0.54× | ||
| Q2 24 | 3.06× | — | ||
| Q1 24 | -0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
